Symbotic에 대한 매도 수량은 투자자에게 Symbotic의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Symbotic (NASDAQ:SYM) 주식, 공매도 수량 보고

Symbotic

Symbotic Inc is an automation technology company that develops technologies to improve operating efficiencies in modern warehouses. The group develops, commercializes, and deploys innovative, end-to-end technology solutions that dramatically improve supply chain operations. Symbotic also automates the processing of pallets and cases in large warehouses or distribution centers for some of the retail and wholesale companies in the world. The company operates in two geographical regions the United States and Canada. Key revenue is generated from the United States.

Large Cap

News

Movers

Trading Ideas

DDOG

ESTC

MSTR

SMCI

SNOW

이들 대형주들은 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 슈퍼 마이크로 컴퓨터(NASDAQ:SMCI)의 주가가 78.42% 급등했다. 회사가 나스닥에 컴플라이언스 플랜을 제출했다고 발표했다.

슈퍼 마이크로 및 심보틱 지난주 최고 성과를 보여준 10개 대형주 중 일부 (11월 18일 - 11월 22일)

Technicals

Topics

Tech

심보틱(NASDAQ:SYM)의 주식은 회사가 4분기 실적이 예상치를 크게 초과한 결과를 발표한 후 화요일에 급등하고 있다. 시장은 4억 7,027만 달러의 매출을 예상했으나, 이 회사는 5억 7,676만 달러의 매출을 보고했다. 또한 주당 5센트의 순이익을 발표했으며, 이는 3센트의 예상치를 상회한 결과이다.

오늘의 주식: 심보틱의 주가 급등 - 그러나 얼마나 오래 지속될까?

Earnings

Pre-Market Outlook

Markets

화요일(19일) 아침 미국 주식 선물이 상승하고 있는 가운데, 오늘 투자자들의 주목을 받을 수 있는 종목은 다음과 같다. 월마트, 에이컴, 로우스, 심보틱 및 메드트로닉

화요일 주목해야 할 주식: 월마트, 에이컴, 로우스, 심보틱 및 메드트로닉

Symbotic Inc

SYMBIO PHARMS LTD S/ADR by Symbio Pharmaceuticals Ltd

SymBio Pharmaceuticals Ltd

Symbol

SYMBOLIC LOGIC INC by Symbolic Logic Inc.

Symbolic Logic Inc

SYMMETRY TECHNOLOGIES INC by Symmetry Technologies, Inc.

Symmetry Technologies Inc

SYMPHONY HOLDINGS ORD by Symphony Holdings, Ltd.

Symphony Holdings Ltd

SYMPHONY INTL HLDGS ORD by Symphony International Holdings Ltd.

Symphony International Holdings Ltd

Symrise AG

Piper Sandler analyst Quinton Gabrielli initiates coverage on Manhattan Associates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>) with a Overweight rating and announces Price Target of $326.

Price Target

Initiation

Analyst Ratings

MANH

Piper Sandler Initiates Coverage On Manhattan Associates with Overweight Rating, Announces Price Target of $326

Benchmark analyst Mark Palmer maintains MicroStrategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) with a Buy and raises the price target from $450 to $650.

Benchmark Maintains Buy on MicroStrategy, Raises Price Target to $650

Barclays analyst Saket Kalia maintains Ncino (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNO#NASDAQ">NCNO</a>) with a Equal-Weight and raises the price target from $34 to $44.

NCNO

Barclays Maintains Equal-Weight on Ncino, Raises Price Target to $44

On Monday, Cassava Sciences Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>) stock plunged after the company released topline data from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42160859/cassava-sciences-topline-phase-3-data-did-not-meet-co-primary-endpoints" rel="noreferrer noopener">Alzheimer&#8217;s disease</a>.
The trial did not meet the pre-specified co-primary, secondary, and exploratory biomarker endpoints.
In July, CEO Rick Barry wrote a letter to shareholders and employees, saying that the company is in the final stages of testing simufilam and has significant&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41065699/sec-charges-cassava-sciences-over-manipulated-alzheimers-trial-data-company-and-former-execs-agre" rel="noreferrer noopener">financial and emotional stakes</a>.
The co-primary endpoints were the change in cognition and function from baseline to the end of the double-blind treatment period at week 52, assessed by the ADAS-COG12 and ADCS-ADL scales, comparing simufilam to placebo.
Simufilam continued to demonstrate an overall favorable safety profile.
&#8220;The results are disappointing&#8230;We took careful measures to enroll patients with mild-to-moderate AD. Despite that, the loss of cognition in the placebo group was less pronounced than was previously reported in other placebo-controlled studies in AD&#8230;&#8221; said&nbsp;Rick Barry, President and Chief Executive Officer.
The company said the failed trial results have impacted its second Phase 3 trial,&nbsp;ReFocus-ALZ, and decided to discontinue ReFocus-ALZ. The company will also be discontinuing the Open Label Extension study.
The complete 52-week dataset will be available from the study along with a large portion of 76-week data.
Cassava will continue to review the data and evaluate the next steps. We plan to share the detailed results at a future medical meeting.
Cassava has been in the headlines for fabricating data from <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41231890/whats-going-on-with-alzheimers-focused-cassava-sciences-on-tuesday" rel="noreferrer noopener">simufilam drug trials</a>.
In September, Cassava Sciences&nbsp;agreed to pay over $40 million to resolve SEC charges over misleading statements related to a Phase 2 trial of the company&#8217;s controversial&nbsp;Alzheimer&#8217;s drug, simufilam.
The SEC also&nbsp;charged&nbsp;Hoau-Yan Wang, a consultant and co-developer of the drug, with manipulating trial results.
The SEC&#8217;s investigation found that in&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/21/08/22653801/cassava-sciences-shares-sink-with-alzheimers-drug-mired-in-controversy" rel="noreferrer noopener">September 2020</a>, Cassava disclosed manipulated data from the trial, which falsely suggested dramatic improvements in Alzheimer&#8217;s biomarkers like total tau and phosphorylated tau.
Price Action: SAVA stock is down 84.2% at $4.19 during the premarket session at last check Monday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42163927/fda-approves-bridgebio-pharmas-drug-for-rare-heart-disease-poised-to-challenge-pfizer-in-lucrative-yet-competitive-market" target="_blank" rel="noreferrer noopener">FDA Approves BridgeBio Pharma&#8217;s Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market</a></li>
</ul>

Biotech

Equities

Health Care

General

SAVA

Cassava Sciences' Controversial Alzheimer's Drug Fails To Hit Primary Goal In Pivotal Study, Halts Late-Stage Studies

Barclays analyst Alexia Dogani maintains ZIM Integrated Shipping (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) with a Underweight and raises the price target from $13.9 to $16.5.

Barclays Maintains Underweight on ZIM Integrated Shipping, Raises Price Target to $16.5

Semler Scientific Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) shares are trading higher Monday. The company launched an offering and provided an update on its Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) <a href="https://www.benzinga.com/pressreleases/24/11/n42160050/semler-scientific-announces-updated-btc-and-atm-activity">holdings</a>.
What Happened: Semler Scientific announced that it acquired 297 Bitcoin for $29.1 million in cash between Nov. 18 and Nov. 22. The company made the purchases at an average price of $97,995 per Bitcoin. 
As of Friday, Semler held a total of 1,570 Bitcoin, acquired for an aggregate of $117.8 million. 
Semler Scientific entered into a Controlled Equity Offering&nbsp;Sales Agreement with Cantor Fitzgerald in August, under which Semler may offer and sell its common stock in an at-the-market offering from time to time.
The company filed a prospectus supplement on Monday to offer an additional $50 million of shares under its existing offering with Cantor, bringing the total offering amount up to $100 million. 
Several crypto-related stocks have rallied in recent weeks as Bitcoin prices have climbed to new all-time highs just below the $100,000 level. Bitcoin was up 0.24% over a 24-hour period, trading at $97,700 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. 
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42155055/crypto-analyst-bitcoin-poised-to-skyrocket-to-180k-and-eventually-top-1m#google_vignette">Crypto Analyst: Bitcoin Poised To Skyrocket To $180K and &#8216;Eventually&#8217; Top $1M</a>
SMLR Price Action: Semler Scientific shares were up 5.11% at $66.90 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Offerings

$BTC

SMLR

What's Going On With Semler Scientific Stock Monday?

JP Morgan analyst Michael Rehaut maintains AZEK Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZEK#NYSE">AZEK</a>) with a Overweight and raises the price target from $48 to $58.

AZEK

JP Morgan Maintains Overweight on AZEK Co, Raises Price Target to $58

Morgan Stanley analyst Erik Woodring reiterates Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) with a Overweight and maintains $273 price target.

Reiteration

AAPL

Morgan Stanley Reiterates Overweight on Apple, Maintains $273 Price Target

JP Morgan analyst Eric Joseph maintains TG Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>) with a Overweight and raises the price target from $30 to $43.

TGTX

JP Morgan Maintains Overweight on TG Therapeutics, Raises Price Target to $43

Morgan Stanley analyst Devin McDermott maintains EQT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) with a Overweight and raises the price target from $45 to $56.

Morgan Stanley Maintains Overweight on EQT, Raises Price Target to $56

Decibel Cannabis Company Inc. (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/DB#TSXV">DB</a>) (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/DBCCF#OTCQB">DBCCF</a>) has completed the second and final closing of its previously announced non-brokered private placement of its common shares at $0.06 per common share.
<h3 class="wp-block-heading">What Happened</h3>
The company said on Monday that, at the second closing of the offering, it issued 19,647,776 common shares for gross proceeds of roughly $1,178,867.
The second closing was in addition to the previously announced first closing in November when Decibel issued 33,503,864 common shares for gross proceeds of approximately $2,010,232.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40577591/decibels-10m-strategy-how-it-could-enhance-your-canadian-cannabis-portfolio">Decibel's $10M Strategy: How It Could Enhance Your Canadian Cannabis Portfolio</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">Why It Matters</h3>
Decibel said the proceeds of the offering will be used to work on and help integrate the integration of AgMedica BioScience Inc. which he company previously<a href="https://www.benzinga.com/markets/cannabis/24/10/41600492/decibel-acquires-agmedica-announces-private-placement-and-third-quarter-guidance"> acquired</a>. The acquisition was arranged through an agreement with Callisto Capital on Oct. 28 and was made in exchange for a $6.3 million unsecured convertible debenture.
Decibel projects that AgMedica could contribute $30 million of net revenue and $4 million of EBITDA in 2025, totaling an anticipated $130 million of net revenue and $25 million of adjusted EBITDA in 2025 on a pro forma basis.
The company recently <a href="https://www.benzinga.com/24/11/42137701/canadian-cannabis-co-decibel-reports-12-yoy-drop-in-q3-revenue-but-increases-gross-margin-to-53">announced</a> its unaudited interim financial results on Thursday for the third quarter revealing CA$24.1 million ($17.2 million) in net revenue representing a 9% increase sequentially, but a 12% decrease year-over-year. However, gross margin before fair value adjustments reached 53% for the period, up from 44% in the prior year&#8217;s period, reflecting improved operational efficiency.
<h3 class="wp-block-heading">What's Next</h3>
The offering is subject to the receipt of all regulatory approvals including the final approval of the TSX Venture Exchange (TSXV).
Now Read:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/08/40369534/decibel-cannabis-reports-22-yoy-decrease-in-q2-net-revenue-plans-to-benefit-with-new-product-lau">Decibel Cannabis Reports 22% YoY Decrease In Q2 Net Revenue, Plans To Benefit With New Product Launches</a></li>
</ul>
<h3 class="wp-block-heading">DBCCF Price Action</h3>
Decibel's shares traded 1.45% higher at $0.0476 per share after the market close on Friday afternoon.

Cannabis

Financing

DBCCF

TSXV:DB

Decibel Cannabis Raises $1.18M, Secures Capital For AgMedica BioScience Integration

Morgan Stanley analyst Angel Castillo maintains Deere (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) with a Overweight and raises the price target from $401 to $450.

Morgan Stanley Maintains Overweight on Deere, Raises Price Target to $450

EQT Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) shares are trading higher after the company announced it entered into a definitive deal with funds managed by Blackstone Credit &amp; Insurance (BXCI) to <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42159491/eqt-announces-3-5-billion-midstream-joint-venture-with-blackstone-credit-insurance" rel="noreferrer noopener">form a new midstream joint venture</a>.
As per the deal, BXCI will provide EQT&nbsp;$3.5 billion of cash consideration in exchange for a non-controlling equity interest in the joint venture.
This values the JV at approximately $8.8 billion, or 12x EBITDA. The deal provides EQT with a substantial equity capital solution at an accretive cost of capital.
EQT will also retain rights to growth projects linked to the contributed assets, including the planned Mountain Valley Pipeline expansion and the MVP Southgate project.
EQT intends to use the proceeds from the transaction to reduce its term loan, revolving credit facility, and redeem or tender senior notes.
Pro-forma for this deal, along with the recent sale of its remaining non-operated assets in northeast Pennsylvania, EQT expects to exit 2024 with approximately $9 billion in net debt.
EQT President and CEO&nbsp;Toby Z. Rice&nbsp;stated, &#8220;This transaction underscores the ultra-high-quality nature of EQT&#8217;s regulated midstream assets, which service one of the strongest power demand growth regions in&nbsp;the United States&nbsp;underpinned by long-term contracts with the region&#8217;s leading utilities.&#8221;
&#8221;Importantly, through this joint venture&nbsp;EQT preserves the benefits of the Equitrans acquisition by retaining the long-term value from synergy capture and growth projects. We look forward to working with Blackstone to optimize the value of these assets and together explore strategic opportunities across its leading portfolio of energy, power and digital infrastructure in the years ahead.&#8221;&nbsp;
EQT Chief Financial Officer&nbsp;Jeremy Knop&nbsp;stated, &#8220;Blackstone is a leader in providing capital solutions to large corporations and we are thrilled to partner with them in this unique transaction, crafting a tailor-made equity financing solution at a price significantly below EQT&#8217;s equity cost of capital while preserving key tax attributes. When we announced the Equitrans acquisition earlier this year, we made an unwavering commitment to debt reduction.&#8221;
&#8221;We have now delivered on that promise, with announced divestitures to date totaling&nbsp;$5.25 billion&nbsp;of projected cash proceeds, above the high-end of our&nbsp;$3 billion-$5 billion&nbsp;asset sale target, and several quarters ahead of schedule.&#8221;
The transaction is subject to customary closing adjustments, required regulatory approvals, and clearances, and is expected to close in the fourth quarter of 2024.
Investors can gain exposure to the stock via Invesco S&amp;P 500 Equal Weight Energy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSPG#NYSE">RSPG</a>) and First Trust Natural Gas ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCG#NYSE">FCG</a>).
Price Action: EQT shares are up 3.22% at $47.40 premarket at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/24/11/41997142/viking-fund-management-sells-big-oil-stocks-in-q3-cuts-tesla-position-in-half-adds-to-largest-position-broadcom" target="_blank" rel="noreferrer noopener">Viking Fund Management Sells Big Oil Stocks In Q3, Cuts Tesla Position In Half, Adds To Largest Position Broadcom</a></li>
</ul>

First Trust ISE-Revere Natural Gas Index Fund

RSPG

EQT Secures $3.5 Billion Boost: Blackstone JV To Power Midstream Expansion

Morgan Stanley analyst Lauren Schenk maintains Chewy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) with a Overweight and raises the price target from $33 to $36.

CHWY

Morgan Stanley Maintains Overweight on Chewy, Raises Price Target to $36

JP Morgan analyst Seth Seifman maintains Boeing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) with a Overweight and lowers the price target from $195 to $190.

JP Morgan Maintains Overweight on Boeing, Lowers Price Target to $190

Benchmark analyst Bill Sutherland downgrades Select Medical Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEM#NYSE">SEM</a>) from Buy to Hold.

Downgrades

Benchmark Downgrades Select Medical Hldgs to Hold

AMC's total domestic revenue for the weekend includes revenue from admissions, along with food &amp; beverage, including merchandise
4.6 million moviegoers watched a movie at AMC Theatres in the United States and at ODEON Cinemas, AMC's international subsidiary, from Thursday to Sunday
ODEON Cinemas recorded its single-day revenue high (admissions plus food &amp; beverage) in 2024 on Saturday, November 23
AMC's domestic merchandise program continues to be popular with guests as WICKED merchandise virtually sold out by Sunday
AMC will participate in the announced WICKED Singalong showtimes, coming to theatres later in December

AMC Theatres Achieves Record Domestic Revenue Pre-Thanksgiving Weekend With 4.6M Moviegoers, Driven by WICKED and GLADIATOR II, ODEON's Single-Day High, Nearly Sold-Out WICKED Merchandise, and Anticipates Upcoming WICKED Singalong Showtimes; No Financial Terms Disclosed

Morgan Stanley analyst Michael Cyprys upgrades Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) from Equal-Weight to Overweight and raises the price target from $24 to $55.

Upgrades

HOOD

Morgan Stanley Upgrades Robinhood Markets to Overweight, Raises Price Target to $55

MSTRRKLBNVDAACHRSAVATSLA$BTCLUNRMARAHOODData from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment " title="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment ">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment </a>
<ul>
<li>MSTR</li>
<li>RKLB</li>
<li>NVDA</li>
<li>ACHR</li>
<li>SAVA</li>
<li>TSLA</li>
<li>$BTC</li>
<li>LUNR</li>
<li>MARA</li>
<li>HOOD</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

ACHR

LUNR

MARA

NVDA

RKLB

TSLA

Top 10 Trending Stocks On WallStreetBets As Of November 25, 2024 (Via Swaggy Stocks)

Bernstein analyst Gautam Chhugani maintains MicroStrategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) with a Outperform and raises the price target from $290 to $600.

Bernstein Maintains Outperform on MicroStrategy, Raises Price Target to $600

In a report released today, Michael Latimore from Northland Securities maintained a Buy rating on Symbotic (SYM – Research Report), with a price ta...

Symbotic (SYM) Receives a Buy from Northland Securities

D.A. Davidson analyst Matt Summerville maintained a Buy rating on Symbotic (SYM – Research Report) today and set a price target of $47.00. The comp...

Symbotic (SYM) Receives a Buy from D.A. Davidson

Northland analyst Michael Latimore raised the firm's price target on Symbotic (SYM) to $53 from $50 and keeps an Outperform rating on the shares fo...

Symbotic price target raised to $53 from $50 at Northland

BWS Financial analyst Hamed Khorsand maintained a Sell rating on Symbotic (SYM – Research Report) today and set a price target of $10.00. Hamed Kho...

Sell Rating for Symbotic Amid Concerns Over Revenue Recognition and Financial Adjustments

Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS – Walmart (WMT) up 3% Berry Global&nbsp;(BERY) ...

Morning Movers: Walmart jumps following quarterly results

Biggest stock movers Tuesday: WMT, SMCI, INCY, and more

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Walmart (WMT) provided a "beat and rai...

Walmart higher, Lowe's lower after earnings: Morning Buzz

Symbotic: Leading Player In Warehouse Automation; Initiate With 'Buy'

Robert W. Baird analyst Robert Mason CFA has maintained their bullish stance on SYM stock, giving a Buy rating on November 19. Robert Mason CFA has...

Symbotic's Strong Q4 Performance and Strategic Growth Initiatives Justify Buy Rating

In a report released today, Matt Summerville from D.A. Davidson maintained a Buy rating on Symbotic (SYM – Research Report), with a price target of...

ACRS

AMZN

APLS

BERY

BLNK

BNTX

CART

CHPT

ESLT

GOOG

GOOGL

IIIV

INCY

INTC

JNPR

JOBY

SABR

SNEJF

SONY

UBER

XPEV

Press Releases

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Symbotic Inc. (SYM)

Legal

Shareholders that lost money on Symbotic Inc.(SYM) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More

Class Action Filed Against Symbotic Inc. (SYM) Seeking Recovery for Investors - Contact Levi & Korsinsky

SYM Investors Have Opportunity to Lead Symbotic Inc. Securities Fraud Lawsuit with the Schall Law Firm

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Symbotic

DEADLINE ALERT for EXTR, PDD, CXM, and SYM: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Symbotic Announces Date for Reporting Fourth Quarter and Fiscal Year 2024 Financial Results

SYMBOTIC ALERT: Bragar Eagel & Squire, P.C. is Investigating Symbotic Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Comments

Symbotic

매도 수량

Symbotic (NASDAQ:SYM) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌